• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Phreesia Announces Fourth Quarter Fiscal 2026 Results

    3/30/26 4:03:00 PM ET
    $PHR
    Real Estate
    Real Estate
    Get the next $PHR alert in real time by email

    Phreesia, Inc. (NYSE:PHR) ("Phreesia" or the "Company") announced financial results today for the fiscal fourth quarter and fiscal year ended January 31, 2026.

    "We achieved several critical financial milestones ahead of our internal targets, including achieving positive GAAP net income ($2.3 million) and crossing $100 million of Adjusted EBITDA1 and $50 million of free cash flow2 ($78.8 million net cash from operating activities) for fiscal year 2026," said CEO and Co-Founder Chaim Indig.

    Please visit the Phreesia investor relations website at ir.phreesia.com to view the Company's Q4 Fiscal 2026 Stakeholder Letter.

    Fiscal Fourth Quarter Ended January 31, 2026 Highlights

    • Total revenue was $127.1 million in the quarter, up 16% year-over-year.
    • Average number of healthcare services clients ("AHSCs") was 4,658 in the quarter, up 7% year-over-year.
    • Total revenue per AHSC was $27,279 in the quarter, up 8% year-over-year. See "Key Metrics" below for additional information.
    • Net income was $1.3 million in the quarter, as compared to net loss of $6.4 million in the same period in the prior year.
    • Adjusted EBITDA1 was $29.4 million in the quarter, as compared to $16.4 million in the same period in the prior year.
    • Net cash provided by operating activities was $33.7 million in the quarter, as compared to $16.3 million in the same period in the prior year.
    • Free cash flow2 was $28.5 million in the quarter, as compared to $9.2 million in the same period in the prior year.
    • Cash, cash equivalents and restricted cash as of January 31, 2026 was $73.8 million, down $32.5 million from October 31, 2025.

    Fiscal Year Ended January 31, 2026 Highlights

    • Total revenue was $480.6 million in fiscal 2026, up 14% year-over-year.
    • AHSCs were 4,514 in fiscal 2026, up 7% year-over-year.
    • Total revenue per AHSC was $106,467 in fiscal 2026, up 7% year-over-year. See "Key Metrics" below for additional information.
    • Net income was $2.3 million in fiscal 2026, as compared to net loss of $58.5 million in fiscal year 2025.
    • Adjusted EBITDA1 was $101.5 million in fiscal 2026, as compared to $36.8 million in fiscal 2025.
    • Net cash provided by operating activities was $78.8 million in fiscal 2026, as compared to $32.4 million in fiscal 2025.
    • Free cash flow2 was $54.4 million in fiscal 2026, as compared to $8.3 million in fiscal 2025.
    • Cash, cash equivalents and restricted cash as of January 31, 2026 was $73.8 million, down from $84.2 million as of January 31, 2025.

    AccessOne Acquisition

    On November 12, 2025 (the "Closing Date"), we completed the acquisition (the "AccessOne Acquisition") of AccessOne Parent Holdings, Inc. and its subsidiaries (collectively, "AccessOne") for consideration transferred of approximately $164 million, including post-closing adjustments. The AccessOne Acquisition expands our addressable market for healthcare payments. Our payment solutions now offer healthcare providers a trusted, scalable, compliant and operationally efficient healthcare payment card that accelerates cash flow.

    The purchase price was funded with a combination of cash and the net proceeds from a new, 364-day $110 million secured term loan (the "Bridge Loan") entered into on the Closing Date.

    Also on the Closing Date, we entered into an amendment (the "Credit Facility Amendment") to our senior ABL facility with Capital One, National Association (as amended, the "Existing Capital One Credit Facility"). The Credit Facility Amendment amended the covenant limiting acquisitions to permit the acquisition of AccessOne, amended the covenant limiting additional indebtedness to accommodate the Bridge Loan, and amended the security interest supporting the Existing Capital One Credit Facility to permit the security interests granted in connection with the Bridge Loan. The amendment included further changes to sections governing mandatory and voluntary prepayments, negative covenants and events of default to accommodate the existence of the Bridge Loan.

    For more information regarding the AccessOne Acquisition, the Bridge Loan and the Credit Facility Amendment, please see our Current Reports on Form 8-K filed with the SEC on September 4, 2025 and November 12, 2025.

    New Capital One Credit Facility and Refinancing

    On March 13, 2026, subsequent to the end of the fiscal year, we completed a refinancing pursuant to which we repaid all outstanding indebtedness and obligations under the Bridge Loan with $92 million of borrowings from a new 5-year, $275 million senior secured revolving credit facility (the "New Capital One Credit Facility") maturing on March 13, 2031. The New Capital One Credit Facility also replaces the Existing Capital One Credit Facility, which had no outstanding borrowings and was terminated on the same date. The unused borrowing capacity on New Capital One Credit Facility is available to the Company for working capital, capital expenditures, permitted acquisitions and general corporate purposes.

    For more information regarding the New Capital One Credit Facility and the termination of the Bridge Loan and the Existing Capital One Credit Facility, please see our Current Report on Form 8-K filed with the SEC on March 16, 2026.

    Fiscal 2027 Outlook

    We are lowering our revenue outlook for fiscal 2027. We expect revenue to be in the range of $510 million to $520 million from a previous range of $545 million to $559 million. As we discussed on our last earnings call in December 2025, we are experiencing shorter visibility into spending commitments by certain pharmaceutical manufacturers. As we enter fiscal 2027, network solutions clients are committing lower spend levels for the second half of fiscal 2027 than we had anticipated last December. Certain clients are committing fewer dollars due to brand-specific dynamics including the impact of regulatory policies. Though we do not believe these developments are signaling a structural shift in demand for Phreesia's solutions, there is now more variability in our internal network solutions revenue forecasting, particularly in the second half of each fiscal year. Our visibility into revenue across the other parts of our business is generally consistent with our views in December 2025. The revenue range provided for fiscal 2027 assumes approximately $37 million of contribution from AccessOne and no additional revenue from potential future acquisitions completed between now and January 31, 2027.

    We are maintaining our Adjusted EBITDA outlook for fiscal 2027. We expect Adjusted EBITDA to be in the range of $125 million to $135 million. Our Adjusted EBITDA outlook implies that we will absorb much of the reduction in our revenue outlook. In addition to our continued confidence in the operating leverage embedded in our model, we have more recently identified significant opportunities to reduce our reliance on manual processes across Phreesia through the adoption of artificial intelligence. Initially, we expect to see efficiencies in our utilization of outsourced resources. We continue to expect improvement in operating leverage across the Company through a focus on efficiency.

    We are maintaining our expectation for AHSC growth in the mid-single-digit percentage range, and we are lowering our outlook for total revenue per AHSC to the low-single-digit percentage range for fiscal 2027, compared to low double-digit growth previously.

    We believe our cash and cash equivalents and cash generated in our normal operations will be sufficient to reach our fiscal 2027 outlook and meet our obligations. As of January 31, 2026 we had $90 million outstanding under the Bridge Loan and no borrowings outstanding under the Existing Capital One Credit Facility.

    Non-GAAP3 Financial Measures

    We have not reconciled our Adjusted EBITDA outlook to GAAP net income (loss) because we do not provide an outlook for GAAP net income (loss) due to the uncertainty and potential variability of other income, net and income tax (benefit) expense, which are reconciling items between Adjusted EBITDA and GAAP net income (loss). Because we cannot reasonably predict such items, a reconciliation of the non-GAAP financial measure outlook to the corresponding GAAP measure is not available without unreasonable effort. We caution, however, that such items could have a significant impact on the calculation of GAAP net income (loss). For further information regarding the non-GAAP financial measures included in this press release, including a reconciliation of GAAP to non-GAAP financial measures and an explanation of these measures, please see "Non-GAAP Financial Measures" below.

    Available Information

    We intend to use our Company website (including our Investor Relations website) as well as our Facebook, X, LinkedIn and Instagram accounts as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.

    Forward-Looking Statements

    This press release includes express or implied statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally relate to future events or our future financial or operating performance and may contain projections of our future results of operations or of our financial information or state other forward-looking information. These statements include, but are not limited to, statements regarding: our future financial and operating performance, including our revenue, operating leverage, Adjusted EBITDA and cash flows; our expectations regarding demand for our solutions and visibility into future revenue; our expectations regarding improvement in operating leverage across the Company through a focus on efficiency; the expected results of the AccessOne Acquisition discussed herein, including anticipated additional revenue, Adjusted EBITDA and AHSCs; our ability to finance our plans to achieve our fiscal 2027 outlook with our current cash balance and cash generated in the normal course of business; and our outlook for fiscal 2027, including our expectations regarding revenue, Adjusted EBITDA, AHSCs and Total revenue per AHSC; and our growth strategies for the AccessOne business, our ability to offer the AccessOne solution to additional clients and our plans to augment our access to capital. In some cases, you can identify forward-looking statements by the following words: "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control, including, without limitation, risks associated with: our ability to effectively manage our growth and meet our growth objectives; our focus on the long-term and our investments in growth; the ability to integrate operations or realize any operational or corporate synergies and other benefits from the AccessOne Acquisition; the competitive environment in which we operate; our ability to comply with the covenants in the New Capital One Credit Facility; changes in market conditions and receptivity to our products and services; our ability to develop and release new products and services and successful enhancements, features and modifications to our existing products and services; our ability to maintain the security and availability of our platform; the impact of cyberattacks, security incidents or breaches impacting our business; changes in laws and regulations applicable to our business model; our ability to make accurate predictions about our industry and addressable market; our ability to attract, retain and cross-sell to healthcare services clients; our ability to continue to operate effectively with a primarily remote workforce and attract and retain key talent; our ability to realize the intended benefits of our acquisitions and partnerships; and difficulties in integrating our acquisitions and investments; artificial intelligence that can impact our business, including by posing security risks to our confidential information, proprietary information and personal data, increasing our regulatory and compliance burden and increasing competition; and other general, market, political, economic and business conditions (including from the results of the U.S. federal government, tariff and trade issues, and the warfare and/or political and economic instability in Ukraine, the Middle East or elsewhere). The forward-looking statements contained in this press release are also subject to other risks and uncertainties, including those listed or described in our filings with the Securities and Exchange Commission ("SEC"), including in our Annual Report on Form 10-K for the fiscal year ended January 31, 2026 that will be filed with the SEC following this press release. The forward-looking statements in this press release speak only as of the date on which the statements are made. We undertake no obligation to update, and expressly disclaim the obligation to update, any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

    This press release includes certain non-GAAP financial measures as defined by SEC rules. We have provided a reconciliation of those measures to the most directly comparable GAAP measures, with the exception of our Adjusted EBITDA outlook for the reasons described above.

    Conference Call Information

    We will hold a conference call on Monday, March 30, 2026, at 5:00 p.m. Eastern Time to review our 2026 fiscal fourth quarter and fiscal 2026 financial results. To participate in our live conference call and webcast, please dial (800) 715-9871 (or (646) 307-1963 for international participants) using conference code number 7404611 or visit the "Events & Presentations" section of our Investor Relations website at ir.phreesia.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

    About Phreesia

    Phreesia is a trusted leader in patient activation, giving healthcare providers, life sciences companies and other organizations tools to help patients take a more active role in their care. Founded in 2005, Phreesia enabled more than 180 million patient visits in 2025—1 in 6 visits across the U.S. This scale allows Phreesia to make meaningful impact across the healthcare ecosystem. Offering patient-driven digital solutions for intake, outreach, education and more, Phreesia enhances the patient experience, drives operational efficiency and improves healthcare outcomes. To learn more, visit phreesia.com.

    ____________________________

    1 Adjusted EBITDA is a non-GAAP measure. We calculate Adjusted EBITDA as net income or loss before interest expense, interest income, income tax (benefit) expense, depreciation and amortization, stock-based compensation expense, loss on extinguishment of debt, other income, net and certain other items that are not considered to reflect our operating activities and performance within the ordinary course of business, such as acquisition- and restructuring-related costs. The calculation of Adjusted EBITDA was updated beginning in Q3 of fiscal 2026 to include an adjustment for acquisition-related costs. Prior periods have not been retroactively adjusted. See "Non-GAAP Financial Measures" for more information and a reconciliation of Adjusted EBITDA to the closest GAAP measure.

    2 Free cash flow is a non-GAAP measure. We calculate free cash flow as net cash (used in) provided by operating activities less capitalized internal-use software development costs and purchases of property and equipment. See the "Non-GAAP Financial Measures" section for a reconciliation of free cash flow to the closest GAAP measure.

    3 GAAP is defined as generally accepted accounting principles in the United States.

     

    Phreesia, Inc.

    Consolidated Balance Sheets

    (in thousands, except share and per share data)

     

     

    January 31, 2026

     

    January 31, 2025

     

    (Unaudited)

     

     

    Assets

     

     

     

    Current:

     

     

     

    Cash, cash equivalents, and restricted cash (including restricted cash of $1,691)

    $

    73,830

     

     

    $

    84,220

     

    Settlement assets

     

    32,999

     

     

     

    29,176

     

    Accounts receivable, net of allowance for doubtful accounts of $1,523 and $1,468 as of January 31, 2026 and 2025, respectively

     

    97,453

     

     

     

    73,617

     

    Cardholder receivables

     

    38,330

     

     

     

    —

     

    Deferred purchase price receivables

     

    18,003

     

     

     

    —

     

    Accrued interest and fees receivables

     

    840

     

     

     

    —

     

    Deferred contract acquisition costs

     

    410

     

     

     

    401

     

    Prepaid expenses and other current assets

     

    17,978

     

     

     

    15,871

     

    Total current assets

     

    279,843

     

     

     

    203,285

     

    Property and equipment, net of accumulated depreciation and amortization of $94,193 and $84,505 as of January 31, 2026 and 2025, respectively

     

    20,332

     

     

     

    23,651

     

    Capitalized internal-use software, net of accumulated amortization of $69,390 and $55,991 as of January 31, 2026 and 2025, respectively

     

    54,270

     

     

     

    52,763

     

    Operating lease right-of-use assets

     

    2,002

     

     

     

    1,477

     

    Deferred contract acquisition costs

     

    338

     

     

     

    583

     

    Intangible assets, net of accumulated amortization of $13,489 and $8,407 as of January 31, 2026 and 2025, respectively

     

    79,761

     

     

     

    28,143

     

    Goodwill

     

    170,064

     

     

     

    75,845

     

    Deferred tax assets

     

    1,593

     

     

     

    —

     

    Other assets

     

    2,442

     

     

     

    2,668

     

    Long-term cardholder receivables

     

    47,723

     

     

     

    —

     

    Long-term deferred purchase price receivables

     

    5,422

     

     

     

    —

     

    Total Assets

    $

    663,790

     

     

    $

    388,415

     

    Liabilities and Stockholders' Equity

     

     

     

    Current:

     

     

     

    Settlement obligations

    $

    32,999

     

     

    $

    29,176

     

    Current portion of debt and finance lease liabilities

     

    7,971

     

     

     

    8,043

     

    Current portion of operating lease liabilities

     

    1,254

     

     

     

    964

     

    Accounts payable

     

    11,477

     

     

     

    5,622

     

    Accrued expenses

     

    41,257

     

     

     

    37,460

     

    Due to healthcare providers

     

    38,056

     

     

     

    —

     

    Deferred revenue

     

    49,522

     

     

     

    32,758

     

    Other current liabilities

     

    705

     

     

     

    —

     

    Total current liabilities

     

    183,241

     

     

     

    114,023

     

    Long-term debt and finance lease liabilities

     

    92,117

     

     

     

    8,150

     

    Operating lease liabilities, non-current

     

    1,107

     

     

     

    646

     

    Long-term due to healthcare providers

     

    45,329

     

     

     

    —

     

    Long-term deferred revenue

     

    244

     

     

     

    119

     

    Long-term deferred tax liabilities

     

    4,498

     

     

     

    484

     

    Other long-term liabilities

     

    47

     

     

     

    185

     

    Total Liabilities

     

    326,583

     

     

     

    123,607

     

    Commitments and contingencies

     

     

     

    Stockholders' Equity:

     

     

     

    Preferred stock, undesignated, $0.01 par value—20,000,000 shares authorized as of both January 31, 2026 and 2025; no shares issued or outstanding as of January 31, 2026 and 2025, respectively

     

    —

     

     

     

    —

     

    Common stock, $0.01 par value—500,000,000 shares authorized as of both January 31, 2026 and 2025; 62,020,186 and 60,083,444 shares issued as of January 31, 2026 and 2025, respectively

     

    620

     

     

     

    601

     

    Additional paid-in capital

     

    1,181,679

     

     

     

    1,111,274

     

    Accumulated deficit

     

    (799,190

    )

     

     

    (801,496

    )

    Accumulated other comprehensive loss

     

    (382

    )

     

     

    (51

    )

    Treasury stock, at cost, 1,355,169 shares as of both January 31, 2026 and 2025

     

    (45,520

    )

     

     

    (45,520

    )

    Total Stockholders' Equity

     

    337,207

     

     

     

    264,808

     

    Total Liabilities and Stockholders' Equity

    $

    663,790

     

     

    $

    388,415

     

    Phreesia, Inc.

    Consolidated Statements of Operations

    (Unaudited)

    (in thousands, except share and per share data)

     

     

    Three months ended

    January 31,

     

    Fiscal year ended

    January 31,

     

     

    2026

     

     

     

    2025

     

     

     

    2026

     

     

     

    2025

     

    Revenue:

     

     

     

     

     

     

     

    Subscription and related services

    $

    55,924

     

     

    $

    51,793

     

     

    $

    219,461

     

     

    $

    196,510

     

    Payment solutions(1)

     

    35,720

     

     

     

    24,676

     

     

     

    121,459

     

     

     

    101,740

     

    Network solutions

     

    35,423

     

     

     

    33,212

     

     

     

    139,671

     

     

     

    121,563

     

    Total revenues

     

    127,067

     

     

     

    109,681

     

     

     

    480,591

     

     

     

    419,813

     

    Expenses:

     

     

     

     

     

     

     

    Cost of revenue (excluding depreciation and amortization)

     

    18,992

     

     

     

    16,507

     

     

     

    71,365

     

     

     

    66,227

     

    Payment solutions expense(1)

     

    21,398

     

     

     

    17,059

     

     

     

    82,758

     

     

     

    68,707

     

    Sales and marketing

     

    24,656

     

     

     

    28,863

     

     

     

    100,243

     

     

     

    121,129

     

    Research and development

     

    30,925

     

     

     

    29,626

     

     

     

    121,481

     

     

     

    117,364

     

    General and administrative

     

    26,965

     

     

     

    18,415

     

     

     

    79,903

     

     

     

    76,597

     

    Depreciation

     

    3,508

     

     

     

    3,172

     

     

     

    12,972

     

     

     

    14,183

     

    Amortization

     

    6,180

     

     

     

    3,651

     

     

     

    18,481

     

     

     

    13,703

     

    Total expenses

     

    132,624

     

     

     

    117,293

     

     

     

    487,203

     

     

     

    477,910

     

    Operating loss

     

    (5,557

    )

     

     

    (7,612

    )

     

     

    (6,612

    )

     

     

    (58,097

    )

    Other income, net

     

    1,273

     

     

     

    2,217

     

     

     

    2,953

     

     

     

    1,956

     

    Loss on extinguishment of debt

     

    (501

    )

     

     

    —

     

     

     

    (501

    )

     

     

    —

     

    Interest expense

     

    (5,807

    )

     

     

    (586

    )

     

     

    (6,953

    )

     

     

    (2,347

    )

    Interest income

     

    269

     

     

     

    605

     

     

     

    2,173

     

     

     

    2,677

     

    Total other (expense) income, net

     

    (4,766

    )

     

     

    2,236

     

     

     

    (2,328

    )

     

     

    2,286

     

    Loss before income tax expense

     

    (10,323

    )

     

     

    (5,376

    )

     

     

    (8,940

    )

     

     

    (55,811

    )

    Income tax benefit (expense)

     

    11,618

     

     

     

    (1,014

    )

     

     

    11,246

     

     

     

    (2,716

    )

    Net income (loss)

    $

    1,295

     

     

    $

    (6,390

    )

     

    $

    2,306

     

     

    $

    (58,527

    )

    Net income (loss) per share attributable to common stockholders:

     

     

     

     

     

     

     

    Basic

    $

    0.02

     

     

    $

    (0.11

    )

     

    $

    0.04

     

     

    $

    (1.02

    )

    Diluted

    $

    0.02

     

     

    $

    (0.11

    )

     

    $

    0.04

     

     

    $

    (1.02

    )

    Weighted-average common shares outstanding:

     

     

     

     

     

     

     

    Basic

     

    60,403,906

     

     

     

    58,277,812

     

     

     

    59,737,915

     

     

     

    57,589,687

     

    Diluted

     

    61,496,901

     

     

     

    58,277,812

     

     

     

    61,494,878

     

     

     

    57,589,687

     

    (1) The revenue line previously labeled "Payment processing fees" has been relabeled "Payment solutions" to reflect the expanded scope of our payments offerings following the AccessOne Acquisition, which closed on November 12, 2025. "Payment solutions" includes all revenue previously presented as "Payment processing fees" and all revenue from the operations acquired in the AccessOne Acquisition. Additionally, "Payment processing expense" has been relabeled "Payment solutions expense" and includes all expenses previously presented as "Payment processing expense" and direct costs of revenue related to the operations acquired in the AccessOne Acquisition. Prior period amounts have not been reclassified, as the Company did not own the acquired operations in prior periods and the change in presentation did not affect any previously reported amounts.

    Phreesia, Inc.

    Consolidated Statements of Comprehensive Income (Loss)

    (Unaudited)

    (in thousands)

     

     

    Three months ended

    January 31,

     

    Fiscal year ended

    January 31,

     

     

    2026

     

     

     

    2025

     

     

     

    2026

     

     

     

    2025

     

    Net income (loss)

    $

    1,295

     

     

    $

    (6,390

    )

     

    $

    2,306

     

     

    $

    (58,527

    )

    Other comprehensive loss:

     

     

     

     

     

     

     

    Net change in unrealized gains (losses) on cash flow hedges

     

    92

     

     

     

    —

     

     

     

    (133

    )

     

     

    —

     

    Change in foreign currency translation adjustments

     

    (114

    )

     

     

    (46

    )

     

     

    (198

    )

     

     

    (51

    )

    Other comprehensive loss

     

    (22

    )

     

     

    (46

    )

     

     

    (331

    )

     

     

    (51

    )

    Comprehensive income (loss)

    $

    1,273

     

     

    $

    (6,436

    )

     

    $

    1,975

     

     

    $

    (58,578

    )

    Phreesia, Inc.

    Consolidated Statements of Cash Flows

    (Unaudited)

    (in thousands)

     

     

    Three months ended

    January 31,

     

    Fiscal year ended

    January 31,

     

     

    2026

     

     

     

    2025

     

     

     

    2026

     

     

     

    2025

     

    Operating activities:

     

     

     

     

     

     

     

    Net income (loss)

    $

    1,295

     

     

    $

    (6,390

    )

     

    $

    2,306

     

     

    $

    (58,527

    )

    Adjustments to reconcile net income (loss) to net cash provided by operating activities:

     

     

     

     

     

     

     

    Depreciation and amortization

     

    9,688

     

     

     

    6,823

     

     

     

    31,453

     

     

     

    27,886

     

    Stock-based compensation expense

     

    18,038

     

     

     

    17,162

     

     

     

    67,452

     

     

     

    66,975

     

    Amortization of deferred financing costs and debt discount

     

    2,792

     

     

     

    62

     

     

     

    2,977

     

     

     

    236

     

    Loss on extinguishment of debt

     

    501

     

     

     

    —

     

     

     

    501

     

     

     

    —

     

    Non-cash gain on settlement

     

    —

     

     

     

    (2,345

    )

     

     

    —

     

     

     

    (2,345

    )

    Cost of Phreesia hardware purchased by customers

     

    194

     

     

     

    625

     

     

     

    1,022

     

     

     

    1,873

     

    Deferred contract acquisition costs amortization

     

    107

     

     

     

    109

     

     

     

    570

     

     

     

    1,815

     

    Non-cash operating lease expense

     

    257

     

     

     

    179

     

     

     

    914

     

     

     

    747

     

    Deferred taxes

     

    (11,830

    )

     

     

    38

     

     

     

    (13,271

    )

     

     

    214

     

    Unrealized gains and losses for fair value option

     

    (1,020

    )

     

     

    —

     

     

     

    (1,020

    )

     

     

    —

     

    Changes in operating assets and liabilities:

     

     

     

     

     

     

     

    Accounts receivable

     

    (8,632

    )

     

     

    (2,254

    )

     

     

    (23,397

    )

     

     

    (8,812

    )

    Collections of principal on receivables originally held for sale to securitization

     

    13,691

     

     

     

    —

     

     

     

    13,691

     

     

     

    —

     

    Accrued Interest Receivable

     

    (446

    )

     

     

    —

     

     

     

    (446

    )

     

     

    —

     

    Prepaid expenses and other assets

     

    3,475

     

     

     

    (5,713

    )

     

     

    (1,393

    )

     

     

    (1,427

    )

    Deferred contract acquisition costs

     

    17

     

     

     

    (280

    )

     

     

    (334

    )

     

     

    (1,045

    )

    Accounts payable

     

    3,629

     

     

     

    (8,432

    )

     

     

    5,261

     

     

     

    (3,234

    )

    Accrued expenses and other liabilities

     

    8,526

     

     

     

    6,384

     

     

     

    2,894

     

     

     

    182

     

    Payment of due to provider for receivables originally held for sale to securitization

     

    (17,588

    )

     

     

    —

     

     

     

    (17,588

    )

     

     

    —

     

    Lease liabilities

     

    (375

    )

     

     

    (202

    )

     

     

    (1,107

    )

     

     

    (824

    )

    Deferred revenue

     

    11,343

     

     

     

    10,490

     

     

     

    8,329

     

     

     

    8,667

     

    Net cash provided by operating activities

     

    33,662

     

     

     

    16,256

     

     

     

    78,814

     

     

     

    32,381

     

    Investing activities:

     

     

     

     

     

     

     

    Collections of cardholder receivables held for investment and deferred purchase price

     

    15,709

     

     

     

    —

     

     

     

    15,709

     

     

     

    —

     

    Acquisitions, net of cash acquired

     

    (153,191

    )

     

     

    —

     

     

     

    (153,191

    )

     

     

    —

     

    Capitalized internal-use software

     

    (2,578

    )

     

     

    (4,268

    )

     

     

    (13,296

    )

     

     

    (15,380

    )

    Purchases of property and equipment

     

    (2,559

    )

     

     

    (2,790

    )

     

     

    (11,101

    )

     

     

    (8,709

    )

    Net cash used in investing activities

     

    (142,619

    )

     

     

    (7,058

    )

     

     

    (161,879

    )

     

     

    (24,089

    )

    Financing activities:

     

     

     

     

     

     

     

    Proceeds from issuance of common stock upon exercise of stock options

     

    374

     

     

     

    429

     

     

     

    1,454

     

     

     

    1,012

     

    Proceeds from employee stock purchase plan

     

    396

     

     

     

    475

     

     

     

    2,371

     

     

     

    2,918

     

    Finance lease payments

     

    (1,156

    )

     

     

    (2,641

    )

     

     

    (6,825

    )

     

     

    (7,811

    )

    Principal payments on financing agreements

     

    (346

    )

     

     

    (311

    )

     

     

    (1,330

    )

     

     

    (1,199

    )

    Debt issuance costs and loan facility fee payments

     

    (3,134

    )

     

     

    —

     

     

     

    (3,190

    )

     

     

    (152

    )

    Financing payments of acquisition-related liabilities

     

    —

     

     

     

    (4,581

    )

     

     

    —

     

     

     

    (6,254

    )

    Proceeds from debt instruments

     

    110,000

     

     

     

    —

     

     

     

    110,000

     

     

     

    —

     

    Principal payments on debt instruments

     

    (20,000

    )

     

     

    —

     

     

     

    (20,000

    )

     

     

    —

     

    Payments due to provider for unfunded receivables

     

    (9,629

    )

     

     

    —

     

     

     

    (9,629

    )

     

     

    —

     

    Net cash provided by (used in) financing activities

     

    76,505

     

     

     

    (6,629

    )

     

     

    72,851

     

     

     

    (11,486

    )

    Effect of exchange rate changes on cash, cash equivalents and restricted cash

     

    (89

    )

     

     

    (89

    )

     

     

    (176

    )

     

     

    (106

    )

    Net (decrease) increase in cash, cash equivalents and restricted cash

     

    (32,541

    )

     

     

    2,480

     

     

     

    (10,390

    )

     

     

    (3,300

    )

    Cash and cash equivalents—beginning of period

     

    106,371

     

     

     

    81,740

     

     

     

    84,220

     

     

     

    87,520

     

    Cash, cash equivalents and restricted cash—end of period

    $

    73,830

     

     

    $

    84,220

     

     

    $

    73,830

     

     

    $

    84,220

     

     

     

     

     

     

     

     

     

    Supplemental information of non-cash investing and financing information:

     

     

     

     

     

     

     

    Non-cash activity related to credit card receivables and deferred purchase price

    $

    17,585

     

     

    $

    —

     

     

    $

    17,585

     

     

    $

    —

     

    Right of use assets acquired in exchange for operating lease liabilities

    $

    —

     

     

    $

    —

     

     

    $

    —

     

     

    $

    1,958

     

    Property and equipment acquisitions through finance leases

    $

    —

     

     

    $

    —

     

     

    $

    —

     

     

    $

    13,709

     

    Purchase of property and equipment and capitalized software included in accounts payable and accrued liabilities

    $

    1,975

     

     

    $

    1,787

     

     

    $

    1,975

     

     

    $

    1,787

     

    Capitalized stock-based compensation

    $

    322

     

     

    $

    356

     

     

    $

    1,286

     

     

    $

    1,362

     

    Issuance of stock to settle liabilities for stock-based compensation

    $

    990

     

     

    $

    1,213

     

     

    $

    12,724

     

     

    $

    11,892

     

    Cash paid for:

     

     

     

     

     

     

     

    Interest

    $

    721

     

     

    $

    735

     

     

    $

    1,614

     

     

    $

    2,194

     

    Income taxes

    $

    249

     

     

    $

    509

     

     

    $

    1,897

     

     

    $

    3,068

     

    Non-GAAP Financial Measures

    This press release and statements made during the above-referenced webcast may include certain non-GAAP financial measures as defined by SEC rules.

    Adjusted EBITDA is a supplemental measure of our performance that is not required by, or presented in accordance with, GAAP. Adjusted EBITDA is not a measurement of our financial performance under GAAP and should not be considered as an alternative to net income or loss or any other performance measure derived in accordance with GAAP, or as an alternative to cash flows from operating activities as a measure of our liquidity. We calculate Adjusted EBITDA as net income or loss before interest expense, interest income, income tax (benefit) expense, depreciation and amortization, stock-based compensation expense, loss on extinguishment of debt, other income, net and certain other items that are not considered to reflect our operating activities and performance within the ordinary course of business, such as acquisition- and restructuring-related costs.

    The calculation of Adjusted EBITDA was updated beginning in the three months ended October 31, 2025 to include an adjustment for acquisition-related costs, which consist primarily of legal, advisory and other professional fees and integration costs related to acquisitions. Management believes adjusting for these acquisition-related costs provides investors with a more consistent period-to-period comparison of our core operating performance and trends. For periods prior to the three months ended October 31, 2025, the calculation of Adjusted EBITDA did not adjust for acquisition-related costs, and prior periods have not been retroactively adjusted.

    We have provided below a reconciliation of Adjusted EBITDA to net income (loss), the most directly comparable GAAP financial measure. We have also presented Adjusted EBITDA in this press release and our Annual Report on Form 10-K to be filed after this press release because it is a key measure used by our management and board of directors to understand and evaluate our core operating performance and trends, to prepare and approve our annual budget, and to develop short and long-term operational plans. In particular, we believe that the exclusion of the amounts eliminated in calculating Adjusted EBITDA can provide a useful measure for period-to-period comparisons of our core business. Accordingly, we believe that Adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and board of directors.

    We have not reconciled our Adjusted EBITDA outlook to GAAP net income (loss) because we do not provide an outlook for GAAP net income (loss) due to the uncertainty and potential variability of other income, net and income tax (benefit) expense, which are reconciling items between Adjusted EBITDA and GAAP net income (loss). Because we cannot reasonably predict such items, a reconciliation of the non-GAAP financial measure outlook to the corresponding GAAP measure is not available without unreasonable effort. We caution, however, that such items could have a significant impact on the calculation of GAAP net income (loss).

    Our use of Adjusted EBITDA has limitations as an analytical tool, and should not be considered in isolation or as a substitute for analysis of our financial results as reported under GAAP. Some of these limitations are as follows:

    • Although depreciation and amortization expense are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future, and Adjusted EBITDA does not reflect cash capital expenditure requirements for such replacements or for new capital expenditure requirements;
    • Adjusted EBITDA does not reflect: (1) changes in, or cash requirements for, our working capital needs; (2) the potentially dilutive impact of non-cash stock-based compensation; (3) tax payments that may represent a reduction in cash available to us; (4) loss on extinguishment of debt; (5) interest expense; (6) interest income; (7) other income, net; or (8) certain other items that are not considered to reflect our operating activities and performance within the ordinary course of business, such as acquisition- and restructuring-related costs; and
    • Other companies, including companies in our industry, may calculate Adjusted EBITDA or similarly titled measures differently, which reduces its usefulness as a comparative measure.

    Because of these and other limitations, you should consider Adjusted EBITDA along with other GAAP-based financial performance measures, including various cash flow metrics, net income (loss) and our GAAP financial results.

    The following table presents a reconciliation of Adjusted EBITDA to net income (loss), the most directly comparable GAAP financial measure, for each of the periods indicated:

    Phreesia, Inc.

    Adjusted EBITDA

    (Unaudited)

     

     

    Three months ended

    January 31,

     

    Fiscal year ended

    January 31,

    (in thousands)

     

    2026

     

     

     

    2025

     

     

     

    2026

     

     

     

    2025

     

    Net income (loss)

    $

    1,295

     

     

    $

    (6,390

    )

     

    $

    2,306

     

     

    $

    (58,527

    )

    Interest expense

     

    5,807

     

     

     

    586

     

     

     

    6,953

     

     

     

    2,347

     

    Interest income

     

    (269

    )

     

     

    (605

    )

     

     

    (2,173

    )

     

     

    (2,677

    )

    Income tax (benefit) expense

     

    (11,618

    )

     

     

    1,014

     

     

     

    (11,246

    )

     

     

    2,716

     

    Depreciation and amortization

     

    9,688

     

     

     

    6,823

     

     

     

    31,453

     

     

     

    27,886

     

    Stock-based compensation expense

     

    18,038

     

     

     

    17,162

     

     

     

    67,452

     

     

     

    66,975

     

    Loss on extinguishment of debt

     

    501

     

     

     

    —

     

     

     

    501

     

     

     

    —

     

    Other income, net

     

    (1,273

    )

     

     

    (2,217

    )

     

     

    (2,953

    )

     

     

    (1,956

    )

    Other items affecting comparability(1)

     

    7,250

     

     

     

    —

     

     

     

    9,223

     

     

     

    —

     

    Adjusted EBITDA

    $

    29,419

     

     

    $

    16,373

     

     

    $

    101,516

     

     

    $

    36,764

     

    (1) For the three months and year ended January 31, 2026, consisted of legal, advisory and other professional fees and integration costs related to the AccessOne Acquisition.

    We calculate free cash flow as net cash provided by operating activities less capitalized internal-use software development costs and purchases of property and equipment.

    Additionally, free cash flow is a supplemental measure of our performance that is not required by, or presented in accordance with, GAAP. We consider free cash flow to be a liquidity measure that provides useful information to management and investors about the amount of cash generated by our business that can be used for strategic opportunities, including investing in our business, making strategic investments, partnerships and acquisitions and strengthening our financial position.

    The following table presents a reconciliation of free cash flow from net cash provided by operating activities, the most directly comparable GAAP financial measure, for each of the periods indicated:

    Phreesia, Inc.

    Free cash flow

    (Unaudited)

     

     

    Three months ended

    January 31,

     

    Fiscal year ended

    January 31,

    (in thousands)

     

    2026

     

     

     

    2025

     

     

     

    2026

     

     

     

    2025

     

    Net cash provided by operating activities

    $

    33,662

     

     

    $

    16,256

     

     

    $

    78,814

     

     

    $

    32,381

     

    Less:

     

     

     

     

     

     

     

    Capitalized internal-use software

     

    (2,578

    )

     

     

    (4,268

    )

     

     

    (13,296

    )

     

     

    (15,380

    )

    Purchases of property and equipment

     

    (2,559

    )

     

     

    (2,790

    )

     

     

    (11,101

    )

     

     

    (8,709

    )

    Free cash flow

    $

    28,525

     

     

    $

    9,198

     

     

    $

    54,417

     

     

    $

    8,292

     

    Phreesia, Inc.

    Supplementary Information

    (Unaudited)

     

     

    Three months ended

    January 31,

     

    Fiscal year ended

    January 31,

    (in thousands)

    2026

     

    2025

     

    2026

     

    2025

    GAAP operating expenses

     

     

     

     

     

     

     

    General and administrative

    $

    26,965

     

    $

    18,415

     

    $

    79,903

     

    $

    76,597

    Sales and marketing

     

    24,656

     

     

    28,863

     

     

    100,243

     

     

    121,129

    Research and development

     

    30,925

     

     

    29,626

     

     

    121,481

     

     

    117,364

    Cost of revenue (excluding depreciation and amortization)

     

    18,992

     

     

    16,507

     

     

    71,365

     

     

    66,227

     

    $

    101,538

     

    $

    93,411

     

    $

    372,992

     

    $

    381,317

    Stock compensation included in GAAP operating expenses

     

     

     

     

     

     

     

    General and administrative

    $

    7,144

     

    $

    6,301

     

    $

    26,337

     

    $

    24,835

    Sales and marketing

     

    5,447

     

     

    5,456

     

     

    20,170

     

     

    21,956

    Research and development

     

    4,483

     

     

    4,213

     

     

    17,014

     

     

    15,262

    Cost of revenue (excluding depreciation and amortization)

     

    964

     

     

    1,192

     

     

    3,931

     

     

    4,922

     

    $

    18,038

     

    $

    17,162

     

    $

    67,452

     

    $

    66,975

    Acquisition-related costs included in GAAP operating expenses

     

     

     

     

     

     

     

    General and administrative

    $

    7,250

     

    $

    —

     

    $

    9,223

     

    $

    —

    Phreesia, Inc.

    Key Metrics

    (Unaudited)

     

     

    Three months ended

    January 31,

     

    Fiscal year ended

    January 31,

     

    2026

     

    2025

     

    2026

     

    2025

    Average number of healthcare services clients ("AHSCs")

     

    4,658

     

     

    4,341

     

     

    4,514

     

     

    4,203

    Total revenue per AHSC

    $

    27,279

     

    $

    25,266

     

    $

    106,467

     

    $

    99,884

    The definitions of our key metrics are presented below.

    • AHSCs. We define AHSCs as the average number of clients that generate subscription and related services or payment solutions revenue each month during the applicable period. In cases where we act as a subcontractor providing white-label services to our partner's clients, we treat the contractual relationship as a single healthcare services client. We believe growth in AHSCs is a key indicator of the performance of our business and depends, in part, on our ability to successfully develop and market our solutions to healthcare services organizations that are not yet clients. We believe growth in AHSCs provides useful information to investors as an important indicator of expected revenue growth. In addition, growth in AHSCs informs our management of the areas of our business that will require further investment to support expected future AHSC growth. For example, as AHSCs increase, we may need to add to our customer support team and invest to maintain effectiveness and performance of our solutions for our healthcare services clients and their patients.
    • Total revenue per AHSC. We define total revenue per AHSC as total revenue in a given period divided by the number of AHSCs during that same period. Our healthcare services clients directly generate subscription and related services and payment solutions revenue. Additionally, our relationships with healthcare services clients who subscribe to our solutions give us the opportunity to engage with life sciences companies, government entities, patient advocacy, public interest and not-for-profit and other organizations who deliver direct communication to patients through our solutions. As a result, we believe that our ability to increase total revenue per AHSC provides useful information to investors as an indicator of the long-term value of our solutions.

    Additional Information

    (Unaudited)

     

     

    Three months ended

    January 31,

     

    Fiscal year ended

    January 31,

     

     

    2026

     

     

     

    2025

     

     

     

    2026

     

     

     

    2025

     

    Patient payment volume (in millions)

    $

    1,128

     

     

    $

    1,080

     

     

    $

    4,873

     

     

    $

    4,420

     

    Payment facilitator volume percentage

    84

    %

    82

    %

    83

    %

    81

    %

    The information above reflects our payment processing operations and does not reflect the operations acquired in the AccessOne Acquisition. As of January 31, 2026, AccessOne had a managed portfolio of cardholder receivables of approximately $419 million. For the fourth quarter of fiscal 2026, Access One's business generated revenues equal to approximately 2.3% of the portfolio.

    • Patient payment volume. We believe that patient payment volume is an indicator of both the underlying health of our healthcare services clients' businesses and the continuing shift of healthcare costs to patients. We measure patient payment volume as the total dollar volume of transactions between our healthcare services clients and their patients utilizing our payment platform, including via credit and debit cards that we process as a payment facilitator as well as cash and check payments and credit and debit transactions for which we act as a gateway to other payment processors.
    • Payment facilitator volume percentage. We define payment facilitator volume percentage as the volume of credit and debit card patient payments that we process as a payment facilitator as a percentage of total patient payment volume. Payment facilitator volume is a major driver of our payment processing fees revenue. Our payment facilitator volume percentage could decline slightly over time should we increase our penetration of enterprise customers that are less likely to use Phreesia as a payment facilitator.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260330072462/en/

    Investor Relations Contact:

    Balaji Gandhi

    Phreesia, Inc.

    [email protected]

    (929) 506-4950

    Media Contact:

    Nicole Gist

    Phreesia, Inc.

    [email protected]

    (407) 760-6274

    Get the next $PHR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PHR

    DatePrice TargetRatingAnalyst
    1/9/2026$30.00Overweight
    Wells Fargo
    1/9/2026$26.00Outperform
    RBC Capital Mkts
    12/9/2025$26.00Overweight
    Barclays
    11/13/2025$32.00Outperform
    BMO Capital Markets
    9/5/2025$33.00Buy
    DA Davidson
    8/27/2025$36.00Outperform
    Mizuho
    1/8/2025$24.00 → $32.00Sector Perform → Outperform
    RBC Capital Mkts
    2/26/2024$35.00Buy
    Truist
    More analyst ratings

    $PHR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on Phreesia with a new price target

    Wells Fargo initiated coverage of Phreesia with a rating of Overweight and set a new price target of $30.00

    1/9/26 9:07:04 AM ET
    $PHR
    Real Estate

    RBC Capital Mkts resumed coverage on Phreesia with a new price target

    RBC Capital Mkts resumed coverage of Phreesia with a rating of Outperform and set a new price target of $26.00

    1/9/26 8:14:39 AM ET
    $PHR
    Real Estate

    Barclays initiated coverage on Phreesia with a new price target

    Barclays initiated coverage of Phreesia with a rating of Overweight and set a new price target of $26.00

    12/9/25 8:52:58 AM ET
    $PHR
    Real Estate

    $PHR
    SEC Filings

    View All

    Phreesia Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Phreesia, Inc. (0001412408) (Filer)

    3/30/26 5:29:40 PM ET
    $PHR
    Real Estate

    Amendment: SEC Form SCHEDULE 13G/A filed by Phreesia Inc.

    SCHEDULE 13G/A - Phreesia, Inc. (0001412408) (Subject)

    3/26/26 2:04:16 PM ET
    $PHR
    Real Estate

    Phreesia Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Phreesia, Inc. (0001412408) (Filer)

    3/16/26 4:04:01 PM ET
    $PHR
    Real Estate

    $PHR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Phreesia Announces Fourth Quarter Fiscal 2026 Results

    Phreesia, Inc. (NYSE:PHR) ("Phreesia" or the "Company") announced financial results today for the fiscal fourth quarter and fiscal year ended January 31, 2026. "We achieved several critical financial milestones ahead of our internal targets, including achieving positive GAAP net income ($2.3 million) and crossing $100 million of Adjusted EBITDA1 and $50 million of free cash flow2 ($78.8 million net cash from operating activities) for fiscal year 2026," said CEO and Co-Founder Chaim Indig. Please visit the Phreesia investor relations website at ir.phreesia.com to view the Company's Q4 Fiscal 2026 Stakeholder Letter. Fiscal Fourth Quarter Ended January 31, 2026 Highlights Total reven

    3/30/26 4:03:00 PM ET
    $PHR
    Real Estate

    Phreesia Named One of Becker's Top Places to Work in Healthcare

    Phreesia, a leader in patient intake, outreach and activation, has been named one of Becker's Healthcare's Top Places to Work in Healthcare for 2026. This marks Phreesia's second time being included on the list, which recognizes hospitals, health systems and healthcare companies that invest in their people through strong benefits, professional development and workplace practices that support engagement and retention. "We're proud to be recognized by Becker's as a top place to work in healthcare," said Amy VanDuyn, Phreesia's SVP of Human Resources. "As a fully remote company, we stay focused on connection, growth and support so our teams can do meaningful work tied to our mission to make

    3/24/26 4:09:00 PM ET
    $PHR
    Real Estate

    Phreesia and Sesame Workshop Win Point of Care Excellence Award for Best Unbranded Campaign

    Phreesia, a leader in patient intake, outreach and activation, and Sesame Workshop, the global nonprofit behind Sesame Street, received the Point of Care Excellence Award for their pediatric health and wellness campaign. The award, announced at the Point of Care Marketing Association's (POCMA) POC Now Summit on March 18, recognizes outstanding campaigns, strategies, and individuals advancing patient and HCP engagement through innovative point-of-care (POC) marketing. The two organizations announced a five-year collaboration in August 2025, and in October launched a six-part campaign to engage millions of parents and caregivers with educational and entertaining messages to help keep thei

    3/19/26 9:03:00 PM ET
    $PHR
    Real Estate

    $PHR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Gandhi Balaji

    4 - Phreesia, Inc. (0001412408) (Issuer)

    3/27/26 5:21:15 PM ET
    $PHR
    Real Estate

    SEC Form 4 filed by Hoffman Allison C

    4 - Phreesia, Inc. (0001412408) (Issuer)

    3/25/26 5:00:22 PM ET
    $PHR
    Real Estate

    SEC Form 4 filed by Pale Fire Capital Se

    4 - Phreesia, Inc. (0001412408) (Issuer)

    3/19/26 6:52:14 PM ET
    $PHR
    Real Estate

    $PHR
    Leadership Updates

    Live Leadership Updates

    View All

    Phreesia and Sesame Workshop Win Point of Care Excellence Award for Best Unbranded Campaign

    Phreesia, a leader in patient intake, outreach and activation, and Sesame Workshop, the global nonprofit behind Sesame Street, received the Point of Care Excellence Award for their pediatric health and wellness campaign. The award, announced at the Point of Care Marketing Association's (POCMA) POC Now Summit on March 18, recognizes outstanding campaigns, strategies, and individuals advancing patient and HCP engagement through innovative point-of-care (POC) marketing. The two organizations announced a five-year collaboration in August 2025, and in October launched a six-part campaign to engage millions of parents and caregivers with educational and entertaining messages to help keep thei

    3/19/26 9:03:00 PM ET
    $PHR
    Real Estate

    Phreesia Joins the Network Advertising Initiative as a Member, Demonstrating Ongoing Commitment to Industry-Leading Privacy Practices

    Phreesia will work with the NAI to shape the national conversation around data privacy and promote consumer choice and transparency As part of the company's ongoing commitment to consumer data privacy, Phreesia is pleased to announce it has joined the Network Advertising Initiative (NAI), a non–profit organization and the leading self-regulatory association dedicated to responsible data collection and use for digital advertising. As a member, Phreesia will work with the NAI to promote consumer-centric privacy practices in healthcare and take a leadership role in shaping the national conversation around data privacy. "We are excited to join the NAI, an organization that shares our dedicati

    10/8/24 6:48:00 AM ET
    $PHR
    Real Estate

    Phreesia's Audrey Gato Named as a Top Woman Leader in SaaS

    Phreesia, a leader in patient intake, outreach and activation, is proud to announce that Audrey Gato, Vice President of Client Solutions, has been named to The Software Report's list of the Top 50 Women Leaders in SaaS of 2023. Honorees were chosen based on their leadership and contributions to the Software-as-a-Service industry. This is the sixth consecutive year a female leader from Phreesia has been named to the list. Previous Phreesia awardees include Allison Hoffman, General Counsel; Kristin Roberts, Vice President of Product Management; Kharen Hauck, Vice President of Marketing; Amy VanDuyn, Senior Vice President of Human Resources; and Sara DiNardo, Vice President of Client Solutio

    1/16/24 4:05:00 PM ET
    $PHR
    Real Estate

    $PHR
    Financials

    Live finance-specific insights

    View All

    Phreesia Announces Fourth Quarter Fiscal 2026 Results

    Phreesia, Inc. (NYSE:PHR) ("Phreesia" or the "Company") announced financial results today for the fiscal fourth quarter and fiscal year ended January 31, 2026. "We achieved several critical financial milestones ahead of our internal targets, including achieving positive GAAP net income ($2.3 million) and crossing $100 million of Adjusted EBITDA1 and $50 million of free cash flow2 ($78.8 million net cash from operating activities) for fiscal year 2026," said CEO and Co-Founder Chaim Indig. Please visit the Phreesia investor relations website at ir.phreesia.com to view the Company's Q4 Fiscal 2026 Stakeholder Letter. Fiscal Fourth Quarter Ended January 31, 2026 Highlights Total reven

    3/30/26 4:03:00 PM ET
    $PHR
    Real Estate

    Phreesia Sets Release Date for Fiscal Fourth Quarter and Fiscal Year 2026 Results

    Phreesia, Inc. (NYSE:PHR) ("Phreesia") today announced that it will release its fiscal fourth quarter and fiscal year 2026 financial results after the close of market trading on Monday, March 30, 2026. Phreesia will issue a press release announcing its quarterly and full year results and the company's quarterly stakeholder letter, both of which will be posted on its investor website at ir.phreesia.com. Phreesia will then hold a conference call to discuss its fiscal fourth quarter and fiscal year 2026 results starting at 5PM Eastern Time on the same day. To participate in the company's live conference call and webcast, please dial (800) 715-9871, or (646) 307-1963 for international partici

    2/17/26 4:05:00 PM ET
    $PHR
    Real Estate

    Phreesia Announces Third Quarter Fiscal 2026 Results and Introduces Fiscal 2027 Outlook

    Phreesia, Inc. (NYSE:PHR) ("Phreesia" or the "Company") announced financial results today for the fiscal third quarter ended October 31, 2025. "I am very proud of our team's strong execution in the fiscal third quarter, which is reflected throughout this letter from our revenue and profit results to product updates and client stories," said CEO and Co-Founder Chaim Indig. Please visit the Phreesia investor relations website at ir.phreesia.com to view the Company's Q3 Fiscal 2026 Stakeholder Letter. Fiscal Third Quarter Ended October 31, 2025 Highlights1 Total revenue was $120.3 million in the quarter, up 13% year-over-year. Average number of healthcare services clients ("AHSCs") was

    12/8/25 4:03:00 PM ET
    $PHR
    Real Estate

    $PHR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Phreesia Inc.

    SC 13G/A - Phreesia, Inc. (0001412408) (Subject)

    11/12/24 10:34:15 AM ET
    $PHR
    Real Estate

    Amendment: SEC Form SC 13G/A filed by Phreesia Inc.

    SC 13G/A - Phreesia, Inc. (0001412408) (Subject)

    7/8/24 4:37:20 PM ET
    $PHR
    Real Estate

    SEC Form SC 13G/A filed by Phreesia Inc. (Amendment)

    SC 13G/A - Phreesia, Inc. (0001412408) (Subject)

    2/16/24 4:57:01 PM ET
    $PHR
    Real Estate